Intellia Therapeutics (NTLA) – Investment Analysts’ Weekly Ratings Changes

Intellia Therapeutics (NASDAQ: NTLA) recently received a number of ratings updates from brokerages and research firms:

• 3/5/2025 – Intellia Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $30.00 price target on the stock.
• 3/4/2025 – Intellia Therapeutics had its price target lowered by analysts at Truist Financial Co. from $90.00 to $50.00. They now have a “buy” rating on the stock.
• 3/3/2025 – Intellia Therapeutics was upgraded by analysts at StockNews.com to a “sell” rating.
• 2/28/2025 – Intellia Therapeutics had its “sell” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $9.00 price target on the stock.
• 2/28/2025 – Intellia Therapeutics had its price target lowered by analysts at Barclays PLC from $55.00 to $26.00. They now have an “overweight” rating on the stock.
• 2/28/2025 – Intellia Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $60.00 to $50.00. They now have an “overweight” rating on the stock.
• 2/28/2025 – Intellia Therapeutics had its price target raised by analysts at Citigroup Inc. from $12.00 to $14.00. They now have a “neutral” rating on the stock.
• 2/28/2025 – Intellia Therapeutics had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $13.00 price target on the stock, down previously from $45.00.
• 2/28/2025 – Intellia Therapeutics had its price target lowered by analysts at Chardan Capital from $91.00 to $68.00. They now have a “buy” rating on the stock.
• 1/27/2025 – Intellia Therapeutics was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $11.00 price target on the stock, down previously from $56.00.
• 1/14/2025 – Intellia Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $19.00 to $12.00. They now have a “neutral” rating on the stock.
• 1/13/2025 – Intellia Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $60.00 to $40.00. They now have an “outperform” rating on the stock.
• 1/10/2025 – Intellia Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $70.00 to $60.00. They now have an “overweight” rating on the stock.
• 1/10/2025 – Intellia Therapeutics had its price target lowered by analysts at BMO Capital Markets from $70.00 to $50.00. They now have an “outperform” rating on the stock.
• 1/10/2025 – Intellia Therapeutics had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $10.00 price target on the stock, down previously from $14.00.

Intellia Therapeutics Stock Down 8.6 %

Shares of Intellia Therapeutics stock opened at $9.46 on Tuesday. The company has a market cap of $979.27 million, a PE ratio of -1.74 and a beta of 1.97. Intellia Therapeutics, Inc. has a 52 week low of $8.30 and a 52 week high of $31.10. The business has a 50 day moving average price of $10.57 and a 200-day moving average price of $14.98.

Insider Buying and Selling at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders sold 29,000 shares of company stock valued at $352,551. Company insiders own 3.20% of the company’s stock.

Hedge Funds Weigh In On Intellia Therapeutics

A number of large investors have recently made changes to their positions in the stock. Capstone Investment Advisors LLC boosted its stake in Intellia Therapeutics by 1.4% during the third quarter. Capstone Investment Advisors LLC now owns 61,129 shares of the company’s stock valued at $1,256,000 after buying an additional 831 shares during the period. KBC Group NV boosted its stake in Intellia Therapeutics by 37.3% during the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after buying an additional 1,020 shares during the period. Axxcess Wealth Management LLC raised its position in Intellia Therapeutics by 5.4% during the third quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock valued at $415,000 after purchasing an additional 1,044 shares in the last quarter. Ensign Peak Advisors Inc raised its position in Intellia Therapeutics by 2.9% during the fourth quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company’s stock valued at $457,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in Intellia Therapeutics by 10.3% during the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company’s stock valued at $320,000 after purchasing an additional 1,538 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.